Prothena (NASDAQ:PRTA - Get Free Report) will likely be announcing its earnings results before the market opens on Thursday, February 20th. Analysts expect the company to announce earnings of ($1.02) per share and revenue of $7.53 million for the quarter. Investors that wish to register for the company's conference call can do so using this link.
Prothena Stock Up 2.0 %
PRTA stock traded up $0.28 during trading hours on Friday, hitting $14.17. The company's stock had a trading volume of 204,629 shares, compared to its average volume of 350,091. The company has a market capitalization of $762.49 million, a PE ratio of -5.71 and a beta of 0.08. Prothena has a 12 month low of $11.70 and a 12 month high of $31.03. The stock has a 50 day moving average price of $14.25 and a two-hundred day moving average price of $16.96.
Wall Street Analyst Weigh In
Several analysts have commented on PRTA shares. StockNews.com downgraded shares of Prothena from a "hold" rating to a "sell" rating in a research report on Tuesday, November 19th. HC Wainwright reissued a "buy" rating and issued a $48.00 target price (down from $84.00) on shares of Prothena in a research report on Friday, December 20th. Bank of America decreased their target price on shares of Prothena from $26.00 to $22.00 and set a "neutral" rating for the company in a research report on Thursday, December 19th. Chardan Capital began coverage on shares of Prothena in a research note on Friday, December 20th. They issued a "buy" rating and a $40.00 price objective for the company. Finally, Oppenheimer boosted their price objective on shares of Prothena from $58.00 to $62.00 and gave the stock an "outperform" rating in a research note on Friday, February 7th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat.com, Prothena has an average rating of "Moderate Buy" and a consensus target price of $46.50.
Check Out Our Latest Analysis on Prothena
Prothena Company Profile
(
Get Free Report)
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.
Further Reading
Before you consider Prothena, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prothena wasn't on the list.
While Prothena currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for March 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
